NCT02149277

Gcsf Injection in Women With Repeated Implantaiton Failure

Effects of Exogenous Recombinant GCSF in Patients With Repeated Implantation Failure - A Randomized Single-blind Trial

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Clinique Ovo · Industry
• Sex: Female
• Age: 18 Years – 37 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to see the impact of intrauterine injection of recombinant GCSF on pregnancy and implantation rate during IVF-ICSI (intracytoplasmic sperm injection) protocols as well as in frozen embryo transfer. In addition, following the injection, the level of G-CSF in the bloodstream will be verified.

Detailed description

Recently, scientists have been interested in G-CSF (Granulocyte - Colony Stimulating Factor) and the latter has seen its use grow in reproductive pathology. G -CSF, a true center pivot, would act concurrently on oocyte quality and endometrial receptivity, improving: * Immune tolerance * The self-healing of oocyte chromosome abnormalities * The adherence of the embryo The injection of G-CSF molecule has been used in different circumstances. One of its uses, among others, is to help rebuild the immune system in patients undergoing chemotherapy. Some studies have been conducted in patients having embryo implantation problems; they have demonstrated improved rates of pregnancy and childbirth after treatment.

Conditions

• Repeated Embryo Implantation Failure

Interventions

Type	Name	Description
DRUG	Filgrastim	The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.

Timeline

• Start date: 2013-03-01
• Primary completion: 2017-12-01
• Completion: 2017-12-01
• First posted: 2014-05-29
• Last updated: 2022-04-27

Locations

1 site across 1 country: Canada